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Abstract
Maternal caffeine consumption is associated with reduced fetal growth, but the underlying molecular mechanisms are
unknown. Since there is evidence that decreased placental 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) is linked
to fetal growth restriction, we hypothesized that caffeine may inhibit fetal growth partly through down regulating placental
11b-HSD2. As a first step in examining this hypothesis, we studied the effects of caffeine on placental 11b-HSD2 activity and
expression using our established primary human trophoblast cells as an in vitro model system. Given that maternal serum
concentrations of paraxanthine (the primary metabolite of caffeine) were greater in women who gave birth to small-for-
gestational age infants than to appropriately grown infants, we also studied the effects of paraxanthine. Our main findings
were: (1) both caffeine and paraxanthine decreased placental 11b-HSD2 activity, protein and mRNA in a concentration-
dependent manner; (2) this inhibitory effect was mediated by the adenosine A2B receptor, since siRNA-mediated
knockdown of this receptor prevented caffeine- and paraxanthine-induced inhibition of placental 11b-HSD2; and (3)
forskolin (an activator of adenyl cyclase and a known stimulator of 11b-HSD2) abrogated the inhibitory effects of both
caffeine and paraxanthine, which provides evidence for a functional link between exposure to caffeine and paraxanthine,
decreased intracellular levels of cAMP and reduced placental 11b-HSD2. Taken together, these findings reveal that placental
11b-HSD2 is a novel molecular target through which caffeine may adversely affect fetal growth. They also uncover
a previously unappreciated role for the adenosine A2B receptor signaling in regulating placental 11b-HSD2, and
consequently fetal development.
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Introduction
Fetal growth restriction (FGR) occurs in 5–10% of all
pregnancies, and it is a leading cause of perinatal morbidity and
mortality [1–4]. Moreover, there is accumulating evidence that
FGR infants are at a greater risk of developing cardiovascular and
metabolic diseases, cognitive defects, and certain cancers later in
life [5–8]. Although it is known that a number of fetal, maternal
and environmental factors contribute to FGR, the etiology of FGR
remains largely unknown (i.e., approx. 60% of FGR are classified
as idiopathic) [1,9,10]. A number of epidemiological studies
indicate that maternal caffeine consumption is associated with an
increased risk of giving birth to small-for-gestational age babies,
although such an association is not robust [11–15]. Indeed, there is
a dose-dependent association between mean caffeine consumption
of .200 mg/day over the course of pregnancy and reductions in
birth weight [12,16,17]. Furthermore, elevated maternal serum
concentrations of paraxanthine, the primary metabolite of
caffeine, were associated with reduced fetal growth [18,19]. Taken
together, these findings suggest that both caffeine and/or its main
metabolite may adversely affect fetal growth and development, but
the underlying molecular mechanisms are unclear.
Given that caffeine is arguably one of the most commonly
consumed substances during pregnancy [20,21], the study of the
molecular mechanisms by which caffeine and its main metabolite
paraxanthine adversely affect fetal growth is a key component of
our overall efforts at unraveling the factors and their underlying
molecular mechanisms that contribute to impaired fetal growth
and development. Pharmacokinetic studies have demonstrated
that caffeine and its metabolites pass readily through the placenta
to the fetus [22,23]. It is also known that maternal caffeine
consumption during pregnancy is associated with reduced
intervillous placental blood flow [24] and impaired placental
development [25], suggesting that the placenta is an important
target by which caffeine influences fetal growth and development.
However, the precise molecular targets within the placenta upon
which caffeine acts are unclear.
Knowing that reduced 11b-hydroxysteroid dehydrogenase type
2 (11b-HSD2, encoded by the HSD11B2 gene) is linked to FGR in
humans [26–28] and HSD11B2 null mice exhibit FGR phenotype
[29], coupled with the findings that the biological function of
caffeine is largely mediated by adenosine receptors whose
activation leads to changes in cAMP levels [30], which are known
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38082to alter placental 11b-HSD2 [31,32], we hypothesized that
caffeine might reduce fetal growth in part by down-regulating
placental 11b-HSD2. As a first step in testing this hypothesis, we
studied the effects of caffeine on placental 11b-HSD2 using our
established primary human trophoblast cells as an in vitro model
system. Given the association between higher maternal serum
concentrations of paraxanthine and reduced fetal growth [18,19],
we also examined the effects of paraxanthine. Finally, we
investigated the molecular mechanisms underlying the effects of
caffeine and paraxanthine on placental 11b-HSD2.
Materials and Methods
Reagents
[1,2,6,72
3H(N)]-Cortisol (80 Ci/mmol) was purchased from
DuPont Canada Inc. (Markam, ON). Non-radioactive cortisol and
cortisone were obtained from Steraloids Inc. (Wilton, NH).
Caffeine, paraxanthine (also known as 1,7-dimethylxanthine) and
forskolin were purchased from Sigma-Aldrich Canada Ltd.
(Oakville, ON). Polyester-backed thin-layer chromatography
(TLC) plates were obtained from Fisher Scientific Ltd. (Nepean,
ON). All solvents used were from VWR Canlab (Mississauga,
ON). Cell culture supplies were obtained from either Invitrogen
Life Technologies (Burlington, ON) or Fisher Scientific. General
molecular biology reagents were from Invitrogen or Pharmacia
Canada Inc. (Baie D’Urte, QC).
Primary Trophoblast Cell Cultures
Placental trophoblast cells were isolated using a modification of
the method of Kliman [33], as described [34]. Ethics approval for
the entire study was obtained from the University of Western
Ontario Ethics Board for Health Sciences Research Involving
Human Subjects, and informed written consent was obtained from
all participants involved in this study. Briefly, human placentas
were obtained from uncomplicated pregnancies at term after
elective cesarean section. Villous tissues were dissected free from
fetal membranes and blood vessels, rinsed in 0.9% w/v NaCl, and
digested with 0.125% v/v trypsin and 0.02% w/v deoxyribonu-
clease-I (Sigma) in DMEM containing 0.05% w/v streptomycin
and gentamicin (Invitrogen) for 60–80 min. The placental cells
were loaded onto a 5–70% v/v Percoll (Sigma) gradient at step
increments of 5% Percoll, and centrifuged at 2,500 g for 20 min to
separate different cell types. Cytotrophoblasts between the density
markers of 1.049 and 1.062 g/ml were collected and plated in 24-
well plates at a density of 1.35610
6 cells/ml in M199 containing
10% FCS (Invitrogen). The cells were maintained at 37uCi n
humidified 5% CO2-95% air (20% O2) for 48 hours. We have
shown previously that the isolated cytotrophoblasts will differen-
tiate into syncytiotrophoblasts over 48 h of culture under
conditions of the present study [34]. After the end of 48 h, the
trophoblast cells (in triplicate) were treated for 48 h (or as
indicated otherwise) with various compounds in the medium
containing 2% FCS. Controls, also in triplicate, received
equivalent volume of vehicle (ethanol or DMSO). Under
conditions of the present study, cell viability was not affected by
either caffeine or paraxanthine treatment.
Assay of 11b-HSD2 Activity - Radiometric Conversion
Assay
The level of 11b-HSD2 activity in intact cells following
different treatment regimes was determined by measuring the
rate of cortisol to cortisone conversion, as described previously
[34]. Briefly, human trophoblast cells were incubated for 1 h at
37uC in serum-free medium containing approx. 100,000 dpm
[
3H]-cortisol and 100 nM unlabelled cortisol. At the end of
incubation, the medium was collected, and steroids extracted.
The extracts were dried, and the residues resuspended. A
fraction of the resuspension was spotted on a TLC plate that
was developed in chloroform/methanol (9:1, v/v). The bands
containing the labelled cortisol and cortisone were identified by
UV light of the cold carriers, cut out into scintillation vials and
counted in Scintisafe
TM Econo 1 (Fisher Scientific). The rate of
cortisol to cortisone conversion was calculated, and the blank
values (defined as the amount of conversion in the absence of
cells) were subtracted, and expressed as percentage of control.
Results are shown as mean 6 SEM.
Determination of 11b-HSD2 Protein - Western Blot
Analysis
Levels of 11b-HSD2 protein were determined with standard
western blot analysis, as described previously [35]. Briefly,
human trophoblast cells were lysed in SDS Sample Buffer
(62.5 mM Tris-HCl, pH 6.8, 2% w/v SDS, 10% v/v glycerol,
50 mM DTT, and 0.01% w/v bromophenol blue). Equal
concentrations of the whole cell lysates were subjected to
a standard 12% SDS-PAGE. After electrophoresis, proteins
were transferred to PVDF transfer membrane (Amersham
Hybond
TM-P, Cat# RPN303F) using a Bio-Rad Mini Transfer
Apparatus. Non-specific antibody binding was blocked with 5%
w/v milk in TTBS (0.1% v/v Tween-20 in TBS) for 1 h at
room temperature. Membranes were then hybridized with
primary antibody (rabbit anti-human 11b-HSD2 antibody,
a generous gift from Dr. Z. Krozowski [36], 0.25 mg/ml; and
rabbit anti-human GAPDH antibody, Cell Signaling, Cat
#2118, 1:5000) overnight at 4uC. After 365 min washes with
TTBS, the membrane was incubated with the appropriate
HRP-labelled second antibody (R & D Systems, Cat# HAF008,
1:1000) for 1 h at room temperature. Proteins were detected by
chemiluminescence (Western Lightning
TM Plus-ECL, PerkinEl-
mer Life and Analytical Sciences, Cat# NEL103001). Densi-
tometry was performed on the radiographs, and the level of
11b-HSD2 protein was expressed as percent of controls.
Assessment of 11b-HSD2 mRNA – Real-time Quantitative
RT-PCR
The relative abundance of 11b-HSD2 mRNA was assessed by
a two-step real-time quantitative RT-PCR (qRT-PCR), as de-
scribed previously [37].
Briefly, total RNA was extracted from cultured cells using
RNeasy Mini Kit (QIAGEN Inc., Mississauga, ON) coupled
with on-column DNase digestion with the RNase-Free DNase
Set (QIAGEN) according to the manufacturer’s instructions.
One microgram of total RNA was reverse-transcribed in a total
volume of 20 ml using the High Capacity complimentary
deoxyribonucleic acid (cDNA) Archive Kit (Applied Biosystems,
Forest City, CA) following the manufacturer’s instructions. For
every RT reaction set, one RNA sample was set up without
reverse-transcriptase enzyme to provide a negative control.
Gene transcript levels of 28S rRNA (house-keeping gene) and
11b-HSD2 were quantified separately by custom-designed
SYBR Green I chemistry-based assays [38]. Briefly, primers
(300 nM each) for human 11b-HSD2 (sense: 59-GGC CAA
GGT TTC CCA GTG A-39, antisense: 59-CAG GGT GTT
TGG GCT CAT GA-39) and those (100 nM) for 28S rRNA
(sense: 59-TTG AAA ATC CGG GGG AGA G-39, antisense:
59-ACA TTG TTC CAA CAT GCC AG-39) were designed
with the Primer Express Software (Applied Biosystems), and the
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Green I assays were performed with the SYBR Green PCR
Master Mix (Applied Biosystems) and a modified universal
thermal cycling condition (2 min at 50uC and 10 min at 95uC,
followed by 40 cycles of 10 sec each at 95uC, 60uC and 72uC)
with the standard disassociation/melting parameters (15 sec
each at 95uC, 60uC and 95uC) on the ABI PRISM 7900HT
H
Sequence Detection System (Applied Biosystems). The specificity
of the SYBR Green I assays was verified by performing melting
curve analyses and by subsequent sequencing of the PCR
products.
Levels of 11b-HSD2 mRNA and 28S rRNA in each RNA
sample were quantified by the relative standard curve method
(Applied Biosystems). Briefly, standard curves for 11b-HSD2 and
28S rRNA were generated by performing a dilution series of the
untreated control cDNA. For each RNA sample, the relative
amount of 11b-HSD2 mRNA and 28S rRNA was obtained, and
the ratio of 11b-HSD2 mRNA to 28S rRNA was calculated. For
each experiment, the amount of 11b-HSD2 mRNA under various
treatment conditions is expressed relative to the amount of
transcript present in the untreated control.
Analysis of Adenosine Receptor Expression - RT–PCR
Expression of the four human adenosine receptors, ADORA1,
ADORA2A, ADORA2B and ADORA3 was analyzed by
standard RT-PCR [39]. Briefly, total RNA was isolated from
cultured trophoblast cells as well as term placental tissues using
RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada) coupled
with on-column DNase digestion with the RNase-Free DNase
Set (Qiagen) according to the manufacturer’s instructions. One
microgram of total RNA was reverse transcribed in a volume of
20 ml with the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA), following the manufacturer’s
instructions. For every RT reaction, one RNA sample was set-
up without reverse transcriptase enzyme to provide a negative
control against possible genomic DNA contamination. The
primers specific for human ADORA1, ADORA2A, ADORA2B
and ADORA3 as well as their expected product sizes are shown
in Table 1. PCR reactions were performed for 35 cycles with
denaturing at 95uC, annealing at 55uC, and extension at 72uC.
PCR products were confirmed with standard restriction enzyme
digestions and sequencing analysis.
siRNA-mediated Knockdown of ADORA2A and ADORA2B
Expression
To determine if ADORA2A and/or ADORA2B is involved in
mediating the effects of caffeine and paraxanthine on placental
11b-HSD2, a siRNA-mediated knockdown approach was utilized
[35,39]. Briefly, the isolated human trophoblast cells were plated
on 24-well plates and cultured under standard conditions for 48 h.
Cells were then transfected with 100 nM of siRNA targeting
human ADORA2A (59-CCA UGU GUU AAA GGA AUA UTT,
39-TTG GUA CAC AAU UUC CUU AUA; GenePharma,
Shanghai, China) and ADORA2B (59-GGC CAU UCU UCU
GUC ACA UTT, 39-TTC CGG UAA GAA GAC AGU GUA;
GenePharma) in Opti-MEM I medium (Invitrogen) containing
2 ml/well of Lipofectamine
TM 2000 (Invitrogen), following the
manufacturer’s instructions. Cells were also transfected in an
identical manner with the transfection agent alone to serve as
controls. At 48 h post-transfection, cells were collected for RT-
PCR, as described above. Alternatively, 12 h after transfection,
cells were treated for 48 h with 500 mM of caffeine or
paraxanthine. At the end of treatment, levels of 11b-HSD2
protein were determined by western blot analysis.
Statistical Analyses
Results are presented as mean 6 SEM of four to six
independent experiments (i.e., tissues from different patients), as
indicated. Data were analyzed using one-way ANOVA followed
by Tukey’s post-hoc test, or Student’s t test as indicated.
Significance was set at p,0.05. Calculations were performed
using SPSS software version 9.0 (Chicago, IL).
Results
Effects of Caffeine on 11b-HSD2 Activity and Expression
Given that changes in enzyme activity are more biologically
meaningful than alterations in enzyme expression, we first
examined the effects of caffeine on placental 11b-HSD2 activity
by treating isolated human trophoblast cells with increasing
concentrations of caffeine (100–500 mM) for 48 h. As shown in
Fig. 1A, this treatment resulted in a concentration-dependent
decrease in levels of 11b-HSD2 activity such that a significant
decrease (p,0.05) was seen at 100 mM with a progressive decrease
at higher caffeine concentrations. We then determined if this
inhibitory effect of caffeine was mediated by altered 11b-HSD2
expression. We found a similar concentration-dependent decrease
in levels of both 11b-HSD2 protein and mRNA following caffeine
treatment (Fig. 1B and 1C).
Effects of Paraxanthine on 11b-HSD2 Activity and
Expression
Given that paraxanthine is the primary metabolite of caffeine in
humans [40], coupled with the findings that maternal serum
concentrations of paraxanthine were higher in women who gave
birth to FGR infants than to appropriately grown infants [18,19],
we determined whether this metabolite also exerts an inhibitory
effect on placenta 11b-HSD2. Indeed, treatment of trophoblast
cells with increasing concentrations of paraxanthine (100–
500 mM) led to a similar concentration-dependent decrease in
Table 1. PCR primers for the four human adenosine receptors and human GAPDH.
Gene name Primer sequence Product size (bp)
ADORA1 Forward: 59- TCTGGGCGGTGAAGGTGAAC Reverse: 59- AGTTGCCGTGCGTGAGGAAG 750
ADORA2A Forward: 59- TGCTTCGTCCTGGTCCTCAC Reverse: 59- GCTCTCCGTCACTGCCAT 754
ADORA2B Forward: 59- CCCTTTGCCATCACCATCAG Reverse: 59- CCTGACCATTCCCACTCTTGA 781
ADORA3 Forward: 59- GCGCCATCTATCTTGACATCTTTT Reverse: 59- CTTGGCCCAGGCATACAGG 460
GAPDH Forward: 59- ACCACAGTCCATGCCATCAC Reverse: 59- TCCACCACCCTGTTGCTGTA 450
doi:10.1371/journal.pone.0038082.t001
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mRNA (Fig. 2C).
Expression of Adenosine Receptors in Human
Trophoblast Cells
As a first step in defining the receptors that mediate the
inhibitory effects of caffeine and paraxanthine on placental 11b-
HSD2, we examined the expression of the four-adenosine
receptors (ADORA1, ADORA2A, ADORA2B and ADORA3)i n
cultured human trophoblast cells, because there is robust evidence
for their involvement in mediating a wide range of caffeine
functions [20]. As shown in Fig. 3, the mRNAs encoding
ADORA2A, ADORA2B and ADORA3 were readily detectable in
cultured human trophoblast cells. In contrast, the ADORA1
mRNA was undetectable in trophoblast cells, although it was
readily detected in total RNA extracts from human placental
tissues (served as positive control) (Fig. 3).
Figure 1. Concentration-dependent effects of caffeine on 11b-
HSD2 activity and expression. Human trophoblast cells were
treated with increasing concentration of caffeine (100–500 mM) for
48 h. At the end of treatment, levels of 11b-HSD2 activity in intact cells
(A) as well as levels of 11b-HSD2 protein (B) and 11b-HSD2 mRNA (C)
were determined by a standard radiometric conversion assay, western
blotting, and qRT-PCR, respectively. Data are presented as mean 6 SEM
of four to five independent experiments (*P,0.05, **P,0.01,
***P,0.001 vs. control).
doi:10.1371/journal.pone.0038082.g001
Figure 2. Concentration-dependent effects of paraxanthine on
11b-HSD2 activity and expression. Human trophoblast cells were
treated with increasing concentration of paraxanthine (PX; 100–
500 mM) for 48 h. At the end of treatment, levels of 11b-HSD2 activity
in intact cells (A) as well as levels of 11b-HSD2 protein (B) and 11b-
HSD2 mRNA (C) were determined by a standard radiometric conversion
assay, western blotting, and qRT-PCR, respectively. Data are presented
as mean 6 SEM of four to five independent experiments (*P,0.05,
**P,0.01, ***P,0.001 vs. control).
doi:10.1371/journal.pone.0038082.g002
Figure 3. Expression of adenosine receptor mRNA in cultured
human trophoblast cells. Total RNA was extracted from cultured
trophoblast cells and from placental villi at term (to serve as a positive
control for ADORA1). One microgram of RNA was used in a standard RT-
PCR to amplify mRNA for the four human adenosine receptors, ADORA1,
ADORA2A, ADORA2B and ADORA3. A fraction of the RT-PCR products
was subjected to electrophoresis on a 1.2% agarose gel. This figure
shows the results of one representative experiment.
doi:10.1371/journal.pone.0038082.g003
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ADORA2A Expression on Caffeine and Paraxanthine
Inhibition of 11b-HSD2
Knowing that caffeine functions as an antagonist for ADORA1,
ADORA2A and ADORA2B but not ADORA3 [20], coupled with
the lack of a detectable level of ADORA1 mRNA in cultured
human trophoblast cells (Fig. 3), we reasoned that ADORA2A
and/or ADORA2B might mediate the inhibitory effects of caffeine
and paraxanthine on placental 11b-HSD2. To examine this
possibility, we used a loss of gene function approach. As shown in
Fig. 4A, transfection of trophoblast cells with a siRNA specific for
human ADORA2B resulted in an 80% reduction in ADORA2B
mRNA abundance. Having established the efficacy of siRNA-
mediated knockdown of ADORA2B expression, we then de-
termined the effects of caffeine and paraxanthine on 11b-HSD2
protein in the ADORA2B knockdown trophoblast cells. As shown
in Fig. 4B and 4C, transient transfection of human trophoblast
cells with ADORA2B-specific siRNA resulted in the complete loss
of the ability of both caffeine and paraxanthine to down-regulate
11b-HSD2 protein expression. In contrast, both caffeine and
paraxanthine were equally effective in reducing 11b-HSD2
protein levels in trophoblast cells transfected with and without
ADORA2A-specific siRNA (Fig. 5).
Effects of Forskolin on Caffeine and Paraxanthine
Inhibition of 11b-HSD2
Given that the activation of ADORA2B leads to increases in
intracellular levels of cAMP [30], which are known to up-regulate
placental 11b-HSD2 expression [31,32], we determined the effects
of forskolin, an activator of adenyl cyclase, on the inhibitory effects
of caffeine and paraxanthine. We reasoned that if caffeine signals
through ADORA2B in trophoblast cells, caffeine treatment should
result in decreases in cAMP levels and the addition of forskolin
should counteract this effect of caffeine, and consequently block
caffeine-induced inhibition of placental 11b-HSD2. Indeed,
treatment of trophoblast cells with forskolin completely abrogated
the inhibitory effect of caffeine on 11b-HSD2 expression (Fig. 6).
Similarly, forskolin also prevented paraxanthine-induced decreases
in levels of 11b-HSD2 protein (Fig. 6).
Discussion
The present study demonstrates for the first time that caffeine
and its main metabolite, paraxanthine, reduce 11b-HSD2 activity
and expression in cultured human trophoblast cells. It also reveals
that the inhibitory effects of caffeine and paraxanthine on
placental 11b-HSD2 are mediated by the adenosine A2B receptor.
Given that both maternal caffeine consumption and reduced
placental 11b-HSD2 are linked to impaired fetal growth, the
present findings suggest that placental 11b-HSD2 may be a novel
molecular target through which caffeine may adversely affect fetal
growth and development.
Although several previous experimental studies reported that
maternal caffeine administration during pregnancy led to reduced
fetal and placental weight in rats [41], mice [42], and monkeys
[43], which corroborates and extends the human epidemiological
observations [15], the molecular mechanisms by which caffeine
inhibits fetal growth had never been explored. Therefore, in the
present study we tested the hypothesis that caffeine reduces fetal
growth partly through inhibition of placental 11b-HSD2. Using
our established primary human trophoblast cells as an in vitro
Figure 4. Effects of siRNA-mediated knockdown of ADORA2B on caffeine and paraxanthine inhibition of 11b-HSD2 expression.
Human trophoblast cells were transfected with 100 nM of ADORA2B siRNA or the transfection agent alone to serve as control. Forty-eight hours after
transfection, cells were lysed, and total RNA extracted and subjected to a semi-quantitative RT-PCR to determine levels of ADORA2B mRNA (A).
GAPDH was used as a control to show the specificity of siRNA mediated knockdown of ADORA2B. Alternatively, 12 h after transfection, cells were
treated for 48 h with or without 500 mM of caffeine (B) or paraxanthine (C). At the end of treatment, levels of 11b-HSD2 11b-HSD2 protein were
determined by western blot analysis. Data are presented as mean 6 SEM of four to five independent experiments (***P,0.001 vs. control).
doi:10.1371/journal.pone.0038082.g004
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metabolite paraxanthine decreased 11b-HSD2 activity and
expression. Importantly, concentrations of caffeine and para-
xanthine used in the present study are comparable to, albeit 2–3
times (at the minimal effective concentration –100 mM) higher
than, those reported in human blood circulation. For instance,
a mean blood caffeine concentration of , 22 mM was reported in
pregnant women at 36 weeks of gestation [44], while a plasma
concentration of 40 mM caffeine and 20 mM paraxanthine was
observed in humans after ingestion of 250 mg of caffeine [45].
Recently, one study showed that plasma levels of caffeine were
between 1–50 mM in umbilical cords of preterm newborns [46].
Thus, if these in vitro findings could be extrapolated to human
pregnancies in vivo, they would suggest that caffeine might inhibit
fetal growth at least in part by down-regulating placental 11b-
HSD2 directly and/or indirectly through its major metabolite,
paraxanthine. Obviously, future studies will be required to
determine if these in vitro findings can be confirmed in an animal
model in vivo. Furthermore, the effects of caffeine on cell fate (e.g.,
proliferation, syncytialization, apoptosis of trophoblast cells) re-
main to be explored.
At micromolar concentrations, both caffeine and its principal
metabolite paraxanthine function as adenosine receptor antago-
nists [20]. Four distinct adenosine receptors have been character-
ized, and they are designated as ADORA1, ADORA2A,
ADORA2B, and ADORA3 [30]. Previous studies showed that all
four adenosine receptors (both mRNA and protein) were detect-
able in human placentas, and their levels of expression were
elevated in preeclamptic placentas [47]. Furthermore, one study
showed that ADORA2B immunoreactivity was present in
syncytiotrophoblast cells of human placenta [48]. In addition,
ADORA3 regulated matrix metalloproteinase 2 expression in
preeclamptic placental explant cultures [49]. As a first step in
determining if adenosine receptors were involved in mediating the
Figure 5. Effects of siRNA-mediated knockdown of ADORA2A on caffeine and paraxanthine inhibition of 11b-HSD2 expression.
Human trophoblast cells were transfected with 100 nM of ADORA2A siRNA or the transfection agent alone to serve as control. Forty-eight hours after
transfection, cells were lysed, and total RNA extracted and subjected to a semi-quantitative RT-PCR to determine levels of ADORA2A mRNA (A).
GAPDH was used as a control to show the specificity of siRNA mediated knockdown of ADORA2A. Alternatively, 12 h after transfection, cells were
treated for 48 h with or without 500 mM of caffeine (B) or paraxanthine (C). At the end of treatment, levels of 11b-HSD2 11b-HSD2 protein were
determined by western blot analysis. Data are presented as mean 6 SEM of four independent experiments (***P,0.001 vs. control).
doi:10.1371/journal.pone.0038082.g005
Figure 6. Effects of forskolin on caffeine and paraxanthine
inhibition of 11b-HSD2 expression. Human trophoblast cells were
pretreated for 2 h with 20 mM of forskolin, and were then treated with
500 mM of caffeine or paraxanthine for 48 h. At the end of treatment,
levels of 11b-HSD2 protein were determined by western blot analysis.
Data are presented as mean 6 SEM of three independent experiments
(**P,0.01, ***P,0.001 vs. control).
doi:10.1371/journal.pone.0038082.g006
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HSD2, we examined the expression of the four-adenosine
receptors in cultured human trophoblast cells with standard RT-
PCR. We showed that although ADORA1 mRNA was undetect-
able, mRNAs encoding ADORA2A, ADORA2B, and ADORA3
were readily detected in trophoblast cells. The lack of detectable
mRNA encoding ADORA1 in cultured trophoblast cells cannot be
attributed to any technical issues, because it was readily detected in
our positive control (i.e., RNA extracted from whole placental
tissues), but seems to contradict with one previous study reporting
the presence of ADORA1 protein in human placental trophoblast
cells [49]. In the absence of control data showing the specificity of
ADORA1 antibody used in the previous study, it is difficult to
reconcile this discrepancy. Obviously, the resolution of this
discrepancy awaits future independent studies.
Given that ADORA1 mRNA was undetectable in trophoblast
cells, coupled with the fact that caffeine does not signal through
ADORA3 [20], we postulated that the inhibitory effects of caffeine
and paraxanthine were likely mediated by ADORA2A and/or
ADORA2B. To test this hypothesis, we used a loss of gene function
approach in which the expression of ADORA2A and ADORA2B
was inhibited with siRNA-mediated knockdown. We showed that
both caffeine and paraxanthine completely lost their ability to
reduce 11b-HSD2 expression in trophoblast cells transfected with
a siRNA specific for ADORA2B. In marked contrast, caffeine and
paraxanthine were equally effective in suppressing 11b-HSD2
expression in trophoblast cells transfected with and without
a siRNA specific for ADORA2A, suggesting that the effects of
caffeine and paraxanthine on placental 11b-HSD2 were mediated
by ADORA2B.
Having established the involvement of ADORA2B in mediating
the inhibitory effects of caffeine and paraxanthine on placental
11b-HSD2, we then explored the role of cAMP in ADORA2B
signaling. Although there is robust evidence that activation of
ADORA2B leads to increases in cAMP levels [30], which are
known to stimulate 11b-HSD2 expression [31,32], and caffeine
functions as an ADORA2B antagonist [20], there is no direct
evidence linking caffeine (or paraxanthine) exposure to decreases
in cAMP levels and reduced 11b-HSD2. To determine if such
a link exists, we treated trophoblast cells with caffeine or
paraxanthine in the presence and absence of forskolin, an
activator of adenyl cyclase and a known stimulator of 11b-
HSD2 [31,32]. We showed that forskolin abrogated the inhibitory
effects of both caffeine and paraxanthine on placental 11b-HSD2.
Taken together, our present findings provide evidence that
caffeine and paraxanthine, via antagonizing ADORA2B, decrease
intracellular cAMP levels and inhibit 11b-HSD2 expression and
activity in cultured human trophoblast cells.
In summary, the present study identifies placental 11b-HSD2 as
a molecular target through which caffeine may reduce fetal
growth. It also uncovers a novel role for the adenosine A2B
receptor signaling in regulating placental 11b-HSD2, and
consequently fetal development.
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